The survival of patients with metastatic prostate cancer (PC) has significantly improved in recent years due to the introduction of combination therapies, including androgen deprivation therapy (ADT) with docetaxel (D), androgen receptor signaling inhibitors (ARSI), or triplet therapy (ADT + ARSI + D) as first-line treatment for metastatic hormone-sensitive prostate cancer (mHSPC) [1,2,3,4,5,6,7,8]. The gene discussed is AR; the disease is pachyonychia congenita.